Johnson & Johnson (NYSE:JNJ) Shares Sold by Glen Eagle Advisors LLC

Glen Eagle Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 106,884 shares of the company’s stock after selling 565 shares during the period. Johnson & Johnson makes up approximately 2.6% of Glen Eagle Advisors LLC’s investment portfolio, making the stock its 9th largest position. Glen Eagle Advisors LLC’s holdings in Johnson & Johnson were worth $15,458,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of JNJ. Tallon Kerry Patrick purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $290,000. Capital & Planning LLC boosted its position in shares of Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares during the period. Taylor & Morgan Wealth Management LLC boosted its position in shares of Johnson & Johnson by 29.4% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 4,572 shares of the company’s stock worth $661,000 after purchasing an additional 1,038 shares during the period. Kera Capital Partners Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $351,000. Finally, Monarch Capital Management Inc. boosted its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Monarch Capital Management Inc. now owns 60,264 shares of the company’s stock worth $8,715,000 after purchasing an additional 790 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $153.58 on Wednesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm’s fifty day simple moving average is $155.87 and its 200-day simple moving average is $153.80. The firm has a market capitalization of $369.52 billion, a price-to-earnings ratio of 23.09, a PEG ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JNJ. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Raymond James decreased their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.